Company Overview

Our Mission

Greystone Pharmaceuticals, Inc. is dedicated to bringing its patented platform of technologies to the global marketplace, using them to improve quality of life and healthcare outcomes for patients, and to lower healthcare costs associated with treatment.

Dedicated to Making a Difference

Wound Care:
For patients living with chronic wounds, every-day activities can be painful and challenging. The incidence of chronic wounds is a growing, global problem. In the United States alone, it is projected that the incidence of chronic wounds will rise significantly, with five to seven million chronic wounds estimated annually. The management and treatment of chronic wounds in the U.S. presently costs an estimated $20 billion per year.

At Greystone Pharmaceuticals, Inc., we have developed innovative new wound care technologies that can help patients with chronic and non-responding wounds lead more active, productive and pain-free lives. Our current product line includes Epi-Max® in the United States and DerMax® and MelMax® in the European Union and the Middle East. Our goal is to become a global leader in the treatment of chronic wounds and to leverage our expertise in wound treatment to develop new products and applications using our innovative Polyhydrated Ionogen (PHI) technology.

ENT:
INDUSTRY OVERVIEW FOR EAR, NOSE AND THROAT

Greystone is using its PHI technology, anti-bacterial and anti-bio film agents in developing and full line of products which show safety and efficacy for intranasal use. Sinusitis is the most frequently reported disease in America with more than 35 million Americans suffering from one form of this disease. Technically, sinusitis is the inflammation of the sinus cavities usually due to a bacterial infection. Most cases of sinusitis are associated with a prior respiratory viral infection - cold or a respiratory allergy - or both.

Subsidiaries

Greystone Pharmaceuticals, Inc. wholly owns a number of subsidiary companies that represent its interest in offering patients and healthcare providers solutions for hard-to-heal wounds and improvement of skin integrity. These include:

  • Dermagenics U.S., Inc. (U.S. Wound Care)
  • Dermagenics BV (Europe & Middle East Wound Care)
  • Greystone Research Group, Inc. (Research & Development)
  • Dermedics, Inc. (Cosmeceuticals)